These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 32314664

  • 1. Five drugs facing key patent expirations and potential generic entry from April to May 2020.
    Friedman Y.
    Pharm Pat Anal; 2020 May; 9(2):41-43. PubMed ID: 32314664
    [Abstract] [Full Text] [Related]

  • 2. Two drugs facing key patent expirations and potential generic entry from July to August 2020.
    Friedman Y.
    Pharm Pat Anal; 2020 Jul; 9(4):137-138. PubMed ID: 32815490
    [Abstract] [Full Text] [Related]

  • 3. Three drugs facing key patent expirations and potential generic entry from June 2020 to July 2020.
    Friedman Y.
    Pharm Pat Anal; 2020 May; 9(3):75-76. PubMed ID: 32539666
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE.
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Canada wins legal battle to set patent rules.
    Webster P.
    CMAJ; 2017 Apr 18; 189(15):E578. PubMed ID: 28420686
    [No Abstract] [Full Text] [Related]

  • 12. Patent watch.
    Harrison C.
    Nat Rev Drug Discov; 2013 Jan 18; 12(1):14-5. PubMed ID: 23274462
    [No Abstract] [Full Text] [Related]

  • 13. Teva v. Eisai: what's the real "controversy"?
    Wang GL.
    Food Drug Law J; 2011 Jan 18; 66(4):631-54, iii. PubMed ID: 24505831
    [Abstract] [Full Text] [Related]

  • 14. Drug patent expirations and the speed of generic entry.
    Bae JP.
    Health Serv Res; 1997 Apr 18; 32(1):87-101. PubMed ID: 9108806
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 18; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 18. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov 28; 62(229):63268-9. PubMed ID: 10177950
    [Abstract] [Full Text] [Related]

  • 19. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
    Jones GH, Carrier MA, Silver RT, Kantarjian H.
    Blood; 2016 Mar 17; 127(11):1398-402. PubMed ID: 26817958
    [Abstract] [Full Text] [Related]

  • 20. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 17; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.